Chlamydia trachomatis infection in primary fallopian tube and high-grade serous ovarian cancers: a pilot study
Received 30 September 2018
Accepted for publication 1 February 2019
Published 22 March 2019 Volume 2019:11 Pages 199—205
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Elie Al-Chaer
Mohamed Laban,1 Eman A Ibrahim,2 Alaa S Hassanin,3 Magda A Nasreldin,4 Amal Mansour,5 Waleed M Khalaf,3 Ahmed M Bahaa Eldin,3 Sherif H Hussain,3 Mohammed S Elsafty,1 Ahmad S Hasanien6
1Gynecologic Oncology Unit, Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 2Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 3Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 4Pathology Department, Early Cancer Detection Unit of Ain Shams Maternity Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 5Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 6Family Medicine Department, Royal Australian College of General Practitioners, Sydney, Australia
Background: The aim of this study was to evaluate the association of Chlamydia trachomatis (CT) infection with primary tubal and high-grade serous ovarian cancers.
Methods: This is a cross-sectional, retrospective study conducted at Ain Shams University Maternity Hospital, Egypt, from February 2008 to October 2017. Sixty-seven paraffin archival blocks specimens were retrieved from cases who underwent staging laparotomy due to high-grade serous ovarian cancer (30 cases), primary tubal serous cancer (25 cases), and control specimens of (12) tubal specimens from cases of benign gynecological conditions. All samples were examined for CT DNA using semiquantitative qRT-PCR.
Results: CT DNA was detected in 84% of high-grade tubal serous cancer, 16.7% of high-grade serous ovarian cancer, and 13.3% in controls (P<0.0005). Mean CT DNA relative quantity was significantly high (256) in tubal carcinoma, in comparison to that in high-grade serous ovarian cancer and controls (13.5 and 0.28, respectively; P<0.0005).
Conclusion: To the best of our knowledge, this is the first report on relation of CT to the tubal serous cancer, so the responsibility of CT tubal infection in the pathogenesis of primary tubal cancer needs to be considered.
Keywords: Chlamydia, DNA, PCR, tubal cancer, ovarian cancer, PFTC
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]